All News
What is JAKne? (5.6.2022)
Dr. Jack Cush reviews the news, journal reports, FDA actions, new side effects and changing prevalence of Gout.
Read Article
Lack of Research Stymies Uptake of Medical Marijuana for Rheumatic Pain
A new review article from CreakyJoints finds that there has been limited progress in understanding the potential of cannabis based therapies for the treatment of pain associated with rheumatic conditions in the past five years because of a lack of standardization of clinical research and barriers to conducting research due to existing federal and state regulations.
Read Article
Acne with JAK Inhibitors
JAK inhibitors have become enormously popular and while their side effect profile has been delineated and reviewed, little mention is made of acne – an adverse event that may affect up to one-quarter of patients taking JAK inhibitors (JAKi).
Read Article
BSR Guideline on Idiopathic Inflammatory Myopathy
The British Society of Rheumatology (BSR) has published evidence-based guidelines for idiopathic inflammatory myopathy (IIM) affecting juvenile and adult-onset disease. This rare condition has an estimated prevalence of 5-15 per 100,000 persons.
Read Article
Allopurinol Use Does Not Increase Mortality in Gout with Chronic Kidney Disease
A population based trial has shown that allopurinol use dose escalation and achieving target uric acid levels (with allopurinol), was not associated with increased mortality in patients with gout and concurrent CKD
Read Article
Trends in Rheumatoid Arthritis Disabililty, Despite Biologics
Disability claims in the U.S. related to rheumatoid arthritis (RA) were just as common in 2015 as in 1999, a government researcher found, against expectations that the advent of biologic therapy would have led to a steady decrease.
Read Article
Upadacitinib FDA Approved for Ankylosing Spondylitis
Abbvie has announced the US Food and Drug Administration has approved upadacitinib (Rinvoq or UPA) for use in adults with active ankylosing spondylitis, who have not responded or been intolerant of one or more TNF blockers. The recommended dose is 15 mg per day.
Read Article
$30 Billion and Counting (4.29.2022)
Dr. Jack Cush reviews the news and journal reports and takes viewer questions this week.
Read Article
Prolonged TNF Inhibitor Use Delays Sacroiliac Progression
While tumour necrosis factor inhibitors (TNFi) have been shown to alter/retard X-ray outcomes in peripheral inflammatory arthritis, the inhibitor effects of TNFi on axial skeletal progression in spondylitis has been difficult to prove, owing to difficulties in study design, identifying best cohorts and a presumed slower rate of change in the spine.
Read Article
Intraarticular Steroids in Hip Osteoarthritis - Do They Work?
The efficacy of ultrasound guided intra-articular hip injection of corticosteroid in adult hip osteoarthritis (HOA) was shown to be effective when added to conventional current treatment. But was this a clinically meaningful outcome?
Read Article
PsA Journal Club - Fecal Transplant & H2H IXE vs ADA
Playback now available! Watch our Tuesday Nite Rheumatology, held April 26th, 2022, which featured a Journal Club panel discussion about two important studies.
Read Article
Pre-exposure Prophylaxis for COVID-19 (4.22.22)
Dr. Jack Cush discusses the news and recent journal reports from last weeks RheumNow.com, and answers viewer questions from #ACA - Ask Cush Anything.
Read Article
COVID-19 Vaccination Uptake and Perceptions in Rheumatic Patients
Putman et al has reported vaccine survey results from the COVID-19 Global Rheumatology Alliance (C19-GRA) in Lancet Rheumatology showing the uptake and vaccine hesitancy among people with rheumatic diseases (RMD).
Survey data from 7005 vaccinated and unvaccinated, adult RMD respondents from 102 countries was analyzed.
Links:
Links:
Links:
Links:
Links:
Dr. John Cush RheumNow ( View Tweet)
Links:
